Leadership
The executive leadership team at QuidelOrtho has a shared ambition; to build a healthier world where more people in more places have access to the critical diagnostic intelligence needed to chart the course ahead.
Together with our bold and brave diagnostic changemakers, we’ll continue to seek new answers, pursue new solutions and create new realities for you, your family, your community and our world.
Leadership
Michael Iskra, Executive Vice President and Chief Commercial Officer of QuidelOrtho Corporation, leads the development and implementation of the company’s integrated global commercial strategy for accelerated growth.
Mr. Iskra has over a decade of global executive leadership experience and more than 30 years in the diagnostics and healthcare products and services industries. He holds significant knowledge and expertise across strategy, sales, marketing, operations and general management.
Mr. Iskra was the Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics from 2020 to 2022. Before assuming the role, Mr. Iskra was Ortho’s President of North America commercial operations, leading the company’s North America customer-facing organization, spanning sales, service and regional marketing, as well as regional commercial support functions.
Prior to Ortho, he served as Senior Vice President of Business Development for Healthways. He previously was the CEO of Simplex Healthcare, general manager of CCS Medical and spent 14 years at Bayer/Siemens Diagnostics in a variety of roles, including head of marketing in Europe, with increasing responsibility.
Mr. Iskra holds a B.A. in International Relations from the University of Delaware. He also completed the Executive Management Program at the University of Notre Dame, Mendoza College of Business, and the General Management Leadership Program at Columbia Business School.
Executive Vice President & Chief Operating Officer
Robert Bujarski, Executive Vice President and Chief Operating Officer of QuidelOrtho Corporation, leads the implementation of the company’s strategy and strengthens operational performance.
Mr. Bujarski has two decades of enterprise experience spanning the full spectrum of operational, commercial, and legal functions within the diagnostics sector.
Mr. Bujarski was the Chief Operating Officer of Quidel Corp. from September 2020 to May 2022, where he architected expansions of the company’s scope and scale and facilitated the seamless integration of Quidel Corp. and Ortho Clinical Diagnostics.
Previously, Mr. Bujarski was Quidel’s Senior Vice President for North America Commercial Operations from July 2019 to September 2020, Senior Vice President, General Counsel from March 2007 to September 2020, Senior Vice President, Business Development from August 2009 to July 2019, and General Counsel and Vice President from July 2005 to March 2007. Prior to joining Quidel, Mr. Bujarski was an associate attorney with the law firm of Gibson, Dunn & Crutcher LLP in its transactions practice group from October 2001 to July 2005.
Mr. Bujarski received his B.A. and J.D. from the University of Arizona.
Chief Financial Officer
Joseph Busky, Chief Financial Officer of QuidelOrtho Corporation, manages global finance and drives value creation to enable growth and long-term value.
Mr. Busky has more than 30 years of experience in corporate and operational finance for large, global companies across diagnostics, medical devices, telecom, and marketing services. He has worked both for publicly owned companies and within private equity-owned settings.
Prior to joining Ortho Clinical Diagnostics in July 2020, Mr. Busky served as Chief Financial Officer for Vyaire Medical, Inc., a global medical device company. Before Vyaire, Mr. Busky was Chief Financial Officer of FDH Velocitel, an engineering services company in the telecom space. Previously, he served seven years as Chief Financial Officer of InnerWorkings, Inc., a global marketing services firm with operations in 33 countries, and held corporate and divisional finance roles for a combined 11 years at Siemens Medical Solutions Diagnostics/Dade Behring Holdings, Inc., Bayer Diagnostics and Diagnostic Products Corporation, including serving as Chief Accounting Officer at Dade Behring.
Mr. Busky holds an MBA with a finance concentration, as well as a BBA in Accounting, from Loyola University in Baltimore. He also has a CPA certification in Maryland.
Chief Information Officer
Louise Brandy, Chief Information Officer of QuidelOrtho Corporation, leads the company’s information technology strategy and staff to enhance business teams’ performance and enable the organization to meet enterprise goals.
Ms. Brandy has over three and half decades of experience and a diverse background of expertise in fields including information technology, business transformation, enterprise architecture and finance/accounting.
Ms. Brandy joined Quidel Corp. as Chief Information Officer in 2022 and assumed the role for QuidelOrtho following Quidel’s acquisition of Ortho Clinical Diagnostics. Prior to joining Quidel, she held a variety of positions including Vice President of Enterprise Applications at Essex Property Trust, VP of Product Development at Real Page Inc, Assistant Controller in GAAP accounting organizations, advisory board member for AWT, Network Chair for Women in Technology International, and interim Chief Information Officer with pharmaceutical, manufacturing, and real estate organizations. Ms. Brandy also serves as a member of Chief, a women’s C-level membership network.
Ms. Brandy holds a B.S. in Business Administration from the University of Phoenix.
Senior Vice President & General Counsel and Secretary
Michelle Hodges, Senior Vice President & General Counsel and Secretary of QuidelOrtho Corporation, heads the legal and compliance group, supporting the company’s global business, and oversees all legal and governance matters affecting the company.
Ms. Hodges has over two decades of professional legal experience, specializing in advising public and private companies on mergers and acquisitions, strategic investments, securities law, and corporate governance.
Ms. Hodges served as Senior Vice President, General Counsel of Quidel Corp. from December 2020 to May 2022. Prior to joining Quidel, Ms. Hodges was a corporate lawyer with the international law firm of Gibson, Dunn & Crutcher LLP from December 1996 through November 2020, serving as a Partner of the firm for 16 years.
Ms. Hodges earned her J.D. and MBA from the University of California, Los Angeles. She earned a Bachelor of Horticultural Science degree with honors from Massey University, New Zealand.
Senior Vice President, Research & Development
Dr. Werner Kroll, Senior Vice President, Research & Development of QuidelOrtho Corporation, oversees R&D innovation for the company’s immunoassay and molecular products, leading groundbreaking developments from initial concept to manufacturability with the goal of improving human health globally.
Dr. Kroll has over three decades of industry experience, holding multiple leadership positions in research and development for major companies in the diagnostics space.
Dr. Kroll served as Senior Vice President, Research & Development of Quidel Corp. from 2014 to 2022, where he facilitated the development of countless industry-defining immunoassay and molecular products. Prior to joining Quidel, Dr. Kroll was Vice President and Global Head of Research and Innovation for Novartis Molecular Diagnostics/Codiagnostics. He has also held senior positions at Novartis Pharmaceuticals, Bayer Diagnostics, Bayer Pharmaceuticals, and AGFA. In addition, Dr. Kroll serves on the board of directors of the European Personalised Medicine Association (EPEMED).
Dr. Kroll received his Ph.D. in Physiological Chemistry from the University of Marburg.
Michael Iskra, Executive Vice President and Chief Commercial Officer of QuidelOrtho Corporation, leads the development and implementation of the company’s integrated global commercial strategy for accelerated growth.
Mr. Iskra has over a decade of global executive leadership experience and more than 30 years in the diagnostics and healthcare products and services industries. He holds significant knowledge and expertise across strategy, sales, marketing, operations and general management.
Mr. Iskra was the Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics from 2020 to 2022. Before assuming the role, Mr. Iskra was Ortho’s President of North America commercial operations, leading the company’s North America customer-facing organization, spanning sales, service and regional marketing, as well as regional commercial support functions.
Prior to Ortho, he served as Senior Vice President of Business Development for Healthways. He previously was the CEO of Simplex Healthcare, general manager of CCS Medical and spent 14 years at Bayer/Siemens Diagnostics in a variety of roles, including head of marketing in Europe, with increasing responsibility.
Mr. Iskra holds a B.A. in International Relations from the University of Delaware. He also completed the Executive Management Program at the University of Notre Dame, Mendoza College of Business, and the General Management Leadership Program at Columbia Business School.
